Trials / Completed
CompletedNCT03199872
RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours
A Phase I/II Study of RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- RhoVac APS · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate safety and immunological response to RhoC peptide vaccine in patients with prostate cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | RV001V | Sc injection |
Timeline
- Start date
- 2017-03-30
- Primary completion
- 2018-08-01
- Completion
- 2019-03-29
- First posted
- 2017-06-27
- Last updated
- 2020-06-09
- Results posted
- 2020-06-09
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT03199872. Inclusion in this directory is not an endorsement.